Introduction {#S1}
============

In an earlier publication from 1955, Hume et al. expressed their skepticism on the feasibility of ABO-incompatible (ABOi) kidney transplantations: "... *we do not feel that renal transplantation in the presence of blood incompatibility is wise*" ([@B1]). Since then, major ABO incompatibility has been considered a contraindication to kidney transplantation. A major breakthrough came in 1982, with the first large study on ABOi kidney transplantation by Alexandre et al. from Belgium ([@B2], [@B3]). Successful desensitization was achieved by repeated plasmapheresis (PP), splenectomy, donor thrombocyte transfusion, and infusion of A or B trisaccharide, together with intensified immunosuppression. One-year graft survival in this study was a remarkable 75%. This led to a wider utilization of ABOi kidney transplantations, first in Japan from the late 1980s, in the US from the mid 1990s, and in Europe from the early 2000s. While, even today, kidney transplantation is best performed in the absence of (major) ABO incompatibility, a large end-stage kidney disease population and an increasing organ shortage result in waiting times for a deceased donor kidney transplant exceeding 5 years in some countries such as Germany. One possibility to reduce the waiting time is the transplantation across ABO antibody barriers. Theoretically, the number of kidney transplantations from living donors can be increased by up to 30% when patients are transplanted across the ABO antibody barrier. With currently existing protocols, as many as 90% of patients with an ABOi living donor may effectively be desensitized and transplanted. The aim of desensitization protocols is the reduction and maintenance of anti-A/B antibodies (isoagglutinins) during the first 2 weeks after transplantation below a threshold that is considered to be safe (e.g., \<1:32 in tube technique). Thereafter, even when anti-A/B antibodies recur at high levels they will not harm the kidney transplant, a phenomenon that is called accommodation. In recent years, graft survival rates after ABOi kidney transplantation nearly equaled those after ABO-compatible (ABOc) procedures.

Herein, we review the latest efforts and results in kidney transplantation across the ABO antibody barrier.

Blood Group Antigens and Antibodies {#S2}
===================================

The ABO antigen system consists of oligosaccharides that are predominantly expressed on red blood cells and are also found on endothelial cells, tubuli, and glomeruli making the ABO antigen system important for kidney transplantation. Patients with different blood groups differ with respect to their antigen density on erythrocytes. Compared to blood group A1 and blood group B individuals, blood group A2 recipients, who make up 20% of all Caucasian individuals with blood group A, have a low expression of blood group antigen molecules (30--50%) on the surface of erythrocytes, which is believed to be responsible for the lower immunogenicity of organs from blood group A2 donors ([@B4], [@B5]). ABOi kidney transplantation with A2 organs has been accomplished with standard immunosuppressive therapy without any additional measures ([@B6]). Of interest, anti-A/B antibodies are formed upon contact with gut bacteria during early infancy. Naturally occurring anti-A/B antibodies are predominantly of the IgM class but especially in blood group O individuals they also consist of IgG and IgA class ([@B7]). While the pathogenic importance of anti-A/B antibodies in solid organ transplantation is well known, the relative contribution of the different immunoglobulin isotypes and their subclasses to organ rejection remains to be elucidated.

Desensitization for ABOi Kidney Transplantation {#S3}
===============================================

Despite the absence of a generally accepted desensitization protocol for the transplantation across the ABO antibody barrier, all currently proposed strategies share some common principles (Figure [1](#F1){ref-type="fig"}A).

![**Overview of desensitization protocols for ABO-incompatible (ABOi) living donor kidney transplantation**. **(A)** Scheme for a standard desensitization protocol performed by the majority of centers with modifications in the utilization of desensitization devices, and **(B)** desensitization protocol for ABOi living donor kidney transplantation at the University of Heidelberg. Anti-CD20 therapy is usually performed with rituximab 375 mg/m^2^, anti-IL-2R therapy is performed with basiliximab 20 mg \[modified from Ref. ([@B8])\]. IA, immunoadsorption; IVIg, intravenous immunoglobulin; PP, plasmapheresis.](fimmu-08-00234-g001){#F1}

These include together with a powerful maintenance immunosuppression one or more of the following: (1)Anti-A/B antibody depletion at the time of transplantation using PP, double-filtration PP/membrane filtration, or selective or unselective immunoadsorption (IA)(2)Modulation of the recipient's immune system by the use of intravenous immunoglobulins (IVIgs)(3)Reduction of the B lymphocyte pool by splenectomy, or more recently by the anti-CD20 antibody rituximab(4)Prevention of the deleterious consequences of complement activation upon anti-A/B antibody binding to the graft endothelium.

Antibody Depletion by Extracorporal Treatment {#S3-1}
---------------------------------------------

Antibody removal strategies may be divided into methods that completely remove plasma proteins such as PP, methods that remove only a specific fraction of the plasma proteins including the immunoglobulins (such as membrane separation), and more specific methods such as unselective or selective IA. While PP is the preferred antibody removal strategy in the US, membrane separation is popular in Japan. Unselective and selective IAs are often used in Europe.

Selective anti-A/B antibody removal is feasible by the Glycosorb columns that contain synthetic terminal trisaccharide A or B blood group antigen linked to a sepharose matrix. In addition, they may also reduce total IgG as well as IgG against polysaccharide antigens such as anti-*Pneumococcus* IgG ([@B9]). In a recent analysis, Wahrmann et al. found single treatments with unselective IA to be more effective than with selective anti-A/B antibody columns in removing anti-A/B IgG (median reduction to 28 versus 59% of baseline, *P* \< 0.001) ([@B10]). In contrast, unselective IA was less effective in the removal of anti-A/B antibodies of the IgM (74 versus 30%, *P* \< 0.001) and IgG3 subclass (72 versus 42%, *P* \< 0.05). The same group found that a combination of membrane separation and unselective IA effectively removed IgG and IgM antibodies and effector molecules such as complement C1q component ([@B11]). No significant differences were found in clinical studies that compared the impact of different IA strategies on clinical outcomes, including anti-A/B antibody reduction, survival, kidney function, rejection episodes, or complications ([@B12]).

Intravenous Immunoglobulins {#S3-2}
---------------------------

Intravenous immunoglobulins are given by many centers before ABOi kidney transplantation to prevent the anti-A/B antibody rebound in the early phase after transplantation. In addition, IVIg infusion is believed to reduce infectious complications by substituting depleted immunoglobulins. As a note of caution, IVIg preparations contain IgG antibodies directed against A/B antigens and can effectively increase anti-A/B antibody titers upon administration ([@B12], [@B13]).

B-Cell Depletion by Splenectomy or Rituximab {#S3-3}
--------------------------------------------

Before the introduction of pharmacological anti-B cell therapies, splenectomy was an integral component for the reduction of the B lymphocyte pool prior to ABOi kidney transplantation. Due to the surgical risk and increased risk of sepsis, splenectomy was gradually substituted by the anti-CD20 antibody rituximab. More recently, several groups completely abandoned anti-B cell therapies from their protocols. Flint et al. reported on 37 patients from Melbourne who underwent ABOi kidney transplantation after antibody removal by PP ([@B14]). Transplantation was accomplished by the use of standard immunosuppressive therapy without rituximab when the patient had reached an anti-A/B antibody titer of less than 1:32 (tube method). Patient and graft survival in this cohort was 100% after a median of 26 months after transplantation. Two antibody-mediated rejection episodes were successfully reversed. We observed in the Collaborative Transplant Study (CTS) a higher rate of death-censored graft loss in ABOi kidney transplant recipients when rituximab was omitted (see below) ([@B15]).

Inhibition of Complement Activation {#S3-4}
-----------------------------------

An emerging new concept in the transplantation across ABO antibody barriers is the inhibition of complement activation upon binding of antibodies to the allograft endothelium. Biglarnia et al. described an intentional simultaneous ABOi kidney pancreas transplantation ([@B16]). Severe antibody-mediated rejection in this patient during anti-A/B antibody rebound was successfully treated by inhibiting the assembly of the membrane attack complex by eculizumab. Stegall et al. performed a single center study to evaluate the efficacy of eculizumab added to conventional therapy in the prevention of antibody-mediated rejection after ABOi living donor kidney transplantation (unpublished, NCT01095887). Patients received eculizumab at the time of transplantation, on day 1 after surgery and weekly thereafter for 4 weeks. The study was terminated after only six patients due to poor enrollment. Two of the six patients reached the primary study endpoint of antibody-mediated rejection after 3 months and two allografts had to be removed during the study period. Therefore, results on the use of eculizumab after ABOi kidney transplantation are inconclusive.

Desensitization Protocols and Survival after ABOi Living Donor Kidney Transplantation {#S4}
=====================================================================================

Table S1 in Supplementary Material gives an overview over studies on ABOi kidney transplantation. The largest cohort of patients after ABOi kidney transplantation with the longest follow-up of more than 20 years is reported from Japan. Most patients were desensitized by double-filtration PP, and splenectomy was more recently replaced by the anti-CD20 antibody rituximab. For the most recent area from 2001 to 2010, patient and graft survival rates for the 1,427 analyzed patients were an excellent 98 and 96% for the first year, and 91 and 83% after 9 years, respectively ([@B17]). Data from the Scientific Registry of Transplant Recipients on the outcomes of 738 ABOi kidney transplantations that were performed between 1995 and 2010 in the US have recently been published ([@B18]). Most patients were desensitized by PP and low-dose IVIg. The cumulative incidence of graft loss during the first year after transplantation was 5.9% in ABOi as compared to only 2.9% in ABOc transplantations and occurred mainly during the first 2 weeks after surgery due to rejection. In 2003, Tydén et al. from Sweden published a protocol for ABOi transplantation that is based on recipient desensitization by selective IA using Glycosorb columns ([@B19]). In addition, splenectomy was replaced by the anti-CD20 antibody rituximab. This protocol led to a renaissance of ABOi kidney transplantation in Europe. Recently, Genberg et al. published their extended experience with this protocol ([@B20]). Of 45 patients desensitized for ABOi kidney transplantation, 43 were eventually transplanted between September 2001 and May 2010 (96%). Overall patient and graft survival after a mean follow-up of 4.5 years was 93 and 91%, respectively. None of the patients experienced early acute antibody-mediated rejection that could be linked to anti-A/B antibodies. Recently, the Freiburg group from Germany compared the results of 100 ABOi kidney transplantations performed between April 1, 2004, and October 28, 2014, with the results of 248 ABOc transplantations performed during the same time period ([@B21]). Using the Stockholm protocol, they achieved in recipients of ABOi transplants a 10-year patient and death-censored graft survival of 99 and 94%, respectively, which did not differ significantly from the 80 and 88% survival rates, respectively, in recipients of ABOc transplants. The rates for antibody- and T-cell-mediated rejections were also not significantly different. A study from the UK showed similar death-censored graft survival in 62 patients 3 years after ABOi kidney transplantation when compared to ABOc controls ([@B22]). However, patient survival in ABOi transplant recipients was reduced due to infectious complications, mostly *Pneumocystis jirovecii* pneumonia.

Since 2006, at our center in Heidelberg, we have been using a protocol for desensitization of ABOi kidney transplant candidates that is very similar to the Swedish protocol (Figure [1](#F1){ref-type="fig"}B) ([@B8], [@B12]). The major difference is the use of unselective instead of selective IA, allowing also the desensitization for HLA-incompatible living donor kidney transplantation. Further differences are the omission of IVIg application and a variable number of IA treatments depending on the strength of anti-A/B antibody. To remove pathogenically relevant anti-A/B antibodies of the IgM class more efficiently, at least one additional PP treatment was performed in all patients the day before surgery as of August 2012 ([@B23]). An early analysis of ABOi kidney transplantations showed successful desensitization of 12 patients after a median of six IA treatments ([@B12]). Anti-A/B titer reduction with unselective IA was comparable to that of a historical control group that received selective IA. In a more recent analysis, we compared 34 ABOi kidney transplant recipients who were desensitized with unselective IA to 68 matched, standard risk living donor kidney recipients ([@B23]). After a median postoperative follow-up of 22 months, graft survival in ABOi kidney transplant recipients was insignificantly lower compared to standard risk recipients (*P* = 0.05). One of the two patient deaths in the ABOi kidney transplant recipients was due to *P. jirovecii* pneumonia at postoperative day 169. This patient death may be attributable to intensified immunosuppression that was applied during desensitization including rituximab. Other important differences between ABOi and standard risk kidney recipients were a higher incidence of BK virus replication (\>10^4^ copies/mL plasma, 21 versus 6%, *P* = 0.04) and BK virus nephropathy (SV 40 positive in biopsy, 12 versus 0%, *P* = 0.01) and a higher prevalence of colonization with multidrug-resistant bacteria (15 versus 1%, *P* = 0.02).

Results from the CTS {#S5}
====================

We recently published 3-year outcomes of 1,420 ABOi kidney transplant recipients who were transplanted at 101 different centers between 2005 and 2012 ([@B15]). Patients were compared to a matched group of ABOc kidney transplant recipients and to all ABOc kidney transplant recipients from centers that performed at least five ABOi procedures. Overall graft, death-censored graft, and patient survival were not statistically significant different between the groups. Early patient survival was reduced in ABOi kidney transplant recipients due to a higher rate of early infection-associated death (*P* = 0.037 versus matched controls and *P* \< 0.001 versus center controls). Specifically, one additional death per 100 patients occurred in the first year after ABOi kidney transplantation from an infectious complication. Figure [2](#F2){ref-type="fig"} provides the updated results for this cohort of 1,420 ABOi kidney transplant recipients ([@B15]). Of note, a trend toward better 3-year death-censored graft survival in patients receiving anti-CD20 therapy (*P* = 0.081) in the meantime has become statistically significant after longer follow-up (*P* = 0.009, Figure [2](#F2){ref-type="fig"}C), suggesting a need for anti-B cell therapies in the setting of ABO incompatibility.

![**Cumulative incidence of (A) death-censored graft survival and (B) patient survival in recipients of an ABO-incompatible (ABOi) living donor graft and matched controls receiving an ABO-compatible (ABOc) living donor graft \[updated Figure 1 of Ref. ([@B15])\]**. **(C)** Cumulative incidence of death-censored graft survival in recipients of an ABOi living donor graft with and without anti-CD20 antibody treatment \[updated Figure 4 of Ref. ([@B15])\]. **(D)** Cumulative incidence of death due to infection in recipients of an ABOi living donor graft and matched controls receiving an ABOc living donor graft \[updated Figure 3 of Ref. ([@B15])\].](fimmu-08-00234-g002){#F2}

Complications and Hurdles of ABOi Kidney Transplantation {#S6}
========================================================

Accomodation versus Rejection {#S6-1}
-----------------------------

In contrast to transplantation in the HLA-sensitized patient, accommodation appears to be a frequent phenomenon after ABOi kidney transplantations and is often associated with C4d deposition in peritubular capillaries of allograft biopsies. An accommodation phenotype may be achieved by the controlled anti-A/B antibody exposure to antigens in the early phase after kidney transplantation. About 2 weeks after successful transplantation, accommodation is established and even high anti-A/B antibody exposure does not harm the kidney transplant. Local upregulation of complement regulatory proteins, like CD45, CD55, and CD59, as a consequence of anti-A/B antibody-dependent inactivation of ERK1/2 signaling pathway are discussed as one possible mechanism ([@B24]).

Infection and Malignancy {#S6-2}
------------------------

There are conflicting results on infectious complications after ABOi kidney transplantation in the literature. A higher frequency of viral infections such as CMV, HSV, VZV, and BK virus, as well as *P. jirovecii* pneumonia, wound, and severe urinary tract infections have been described ([@B22], [@B25], [@B26]). In the CTS and the Heidelberg cohort, an increased risk for early severe infections was observed, resulting in approximately one additional patient death in 100 ABOi kidney transplant recipients during the first year after surgery ([@B15], [@B23]). We and others also observed a higher incidence of BK virus replication and BK virus-associated nephropathy ([@B23]). Of note, in a study by Sharif et al., the rate of BK virus nephropathy was about three times higher in ABOi patients compared to patients with HLA antibodies, despite comparable immunosuppressive therapy ([@B27]). Bentall et al. hypothesized that different blood group antigens may influence binding of viral pathogen receptors to sialic acid on renal tubular cells ([@B28]).

Hall et al. found no increased cancer risk when comparing 318 ABOi kidney transplant recipients to matched ABOc controls ([@B29]). The analysis of 1,420 ABOi transplantations from the CTS study also did not show an increased risk of malignancy in ABOi compared to ABOc patients ([@B15]).

Additional Observations {#S6-3}
-----------------------

A study from the US Renal Data System registry found a two times higher risk of early hemorrhage in 119 ABOi kidney transplant recipients when compared to ABOc controls (adjusted HR, 1.96, *P* \< 0.05) ([@B26]). A higher bleeding risk was also found in a cohort of pediatric kidney transplant recipients with two major bleeding episodes in three patients, which was attributed to the unspecific binding of coagulation factors during repeated IA ([@B30]). This assumption is supported by the findings of de Weerd et al. who found a significant correlation between the number of pretransplant apheresis treatments and the peri- and posttransplant bleeding risk ([@B31]).

Some authors observed an increased rate of surgical complications after ABOi kidney transplantation, which were attributed to early intensified immunosuppression with mycophenolic acid and removal of coagulation factors by apheresis. The Freiburg group reported a significantly higher number of lymphoceles in ABOi patients than in ABOc controls (33 versus 15%; *P* = 0.003) that required surgical revisions in 20 and 8% (*P* = 0.013) of patients, respectively ([@B21]). Also, the overall need for surgical revision was significantly higher in ABOi patients compared to ABOc controls (38 versus 24%, *P* = 0.032).

Future Perspectives {#S7}
===================

A new strategy that may come into clinics in the future is the reduction of blood group antigen levels in the allograft by *ex vivo* infusion of endo-beta-galactosidase ([@B32]).

Another approach is the complete avoidance of the ABO antibody barrier by kidney exchange programs. However, despite the usage of large kidney exchange programs, including the utilization of altruistic donors, the blood group O recipients accumulated on the waiting list in different studies ([@B33]). Desensitization for ABOi kidney transplantation was the only way to transplant these patients within a reasonable period of time.

Conclusion {#S8}
==========

In recent years, ABOi kidney transplantation has become a routine procedure. By this approach, about 30% of living donors who were refused in the past can now donate their kidneys and thereby significantly expand the living donor pool. Transplantation in the presence of major ABO incompatibility, however, places the patient at a somewhat higher risk of early rejection, infection, and infection-associated death. Therefore, whenever possible, ABOc procedures should be preferred.
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